Analysts Offer Insights on Healthcare Companies: Petiq (PETQ) and Spruce Biosciences (SPRB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Petiq (PETQ – Research Report) and Spruce Biosciences (SPRB – Research Report) with bullish sentiments.

Petiq (PETQ)

Benchmark Co. analyst John Lawrence reiterated a Buy rating on Petiq today and set a price target of $30.00. The company’s shares closed last Monday at $10.59.

According to TipRanks.com, Lawrence is a 1-star analyst with an average return of -4.8% and a 51.9% success rate. Lawrence covers the Consumer Goods sector, focusing on stocks such as Casey’s General, Kirkland’s, and Boot Barn.

Currently, the analyst consensus on Petiq is a Moderate Buy with an average price target of $30.00.

See today’s best-performing stocks on TipRanks >>

Spruce Biosciences (SPRB)

RBC Capital analyst Gregory Renza maintained a Buy rating on Spruce Biosciences today and set a price target of $8.00. The company’s shares closed last Monday at $2.71.

According to TipRanks.com, Renza is a 4-star analyst with an average return of 5.2% and a 40.6% success rate. Renza covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Prometheus Biosciences, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spruce Biosciences with a $11.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.